Real-world treatment patterns and outcomes in Indian patients with HR+/HER2- advanced breast cancer treated with palbociclib
{{output}}
Background: Palbociclib, a CDK4/6 inhibitor, was approved by FDA in 2015 for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). It was approve... ...
